NASDAQ: EIGREiger Biopharmaceuticals Inc Stock
$0.31-0.01 (-3.13%)
Updated Dec 8, 2023
EIGR Price
$0.31
Fair Value Price
$0.65
Market Cap
$13.58M
52 Week Low
$0.21
52 Week High
$2.98
P/E
-0.16x
P/B
-8.47x
P/S
0.92x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.67M
Earnings
-$86.65M
Gross Margin
98.2%
Operating Margin
-554.93%
Profit Margin
-590.8%
Debt to Equity
-35.7
Operating Cash Flow
-$83M
Beta
1.15
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
EIGR Overview
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how EIGR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EIGR ($0.31) is undervalued by 52.89% relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EIGR ($0.31) is significantly undervalued by 52.89% relative to our estimate of its Fair Value price of $0.65 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EIGR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EIGR due diligence checks available for Premium users.
Be the first to know about important EIGR news, forecast changes, insider trades & much more!
EIGR News
Valuation
EIGR fair value
Fair Value of EIGR stock based on Discounted Cash Flow (DCF)
Price
$0.31
Fair Value
$0.65
Undervalued by
52.28%
EIGR ($0.31) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EIGR ($0.31) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EIGR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EIGR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.16x
Industry
11.7x
Market
31.32x
EIGR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-8.47x
Industry
5.42x
EIGR's financial health
Profit margin
Revenue
$3.2M
Net Income
-$18.0M
Profit Margin
-561.9%
EIGR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EIGR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$55.7M
Liabilities
$57.3M
Debt to equity
-35.7
EIGR's short-term assets ($54.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EIGR's short-term assets ($54.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EIGR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EIGR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.6M
Investing
$19.0M
Financing
$15.0k
EIGR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EIGR vs Biotech Stocks
Eiger Biopharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.